‘Strategic Decision’ Prompts Janssen Exit From Chi-Med Deal
This article was originally published in PharmAsia News
One of the largest collaborative deals in China’s pharmaceutical industry has fallen apart, as Janssen has opted to terminate an R&D alliance agreement in the inflammation/immunology area with Hutchison China MediTech, although the two firms intend to continue to work together in other areas.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.